Gsk (GSK) Current Deferred Revenue (2016 - 2018)

Gsk (GSK) has 3 years of Current Deferred Revenue data on file, last reported at $277.9 million in Q4 2018.

• For the quarter ending Q4 2018, Current Deferred Revenue fell 12.77% year-over-year to $277.9 million; the trailing twelve-month figure through Dec 2018 stood at $277.9 million (down 12.77% YoY), and the FY2018 full-year result was $288.5 million, down 6.69% from the prior year.
• Current Deferred Revenue was $277.9 million for Q4 2018 at Gsk, down from $318.6 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $318.6 million in Q4 2017 to a low of $196.4 million in Q4 2016.
• A 3-year average of $264.3 million and a median of $277.9 million in 2018 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue soared 62.22% in 2017 and dropped 12.77% in 2018, its largest moves.
• Gsk's Current Deferred Revenue stood at $196.4 million in 2016, then surged by 62.22% to $318.6 million in 2017, then declined by 12.77% to $277.9 million in 2018.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $277.9 million in Q4 2018, $318.6 million in Q4 2017, and $196.4 million in Q4 2016.